Iobitridol

File:Iobitridol.png

Iobitridol

Iobitridol stands as a vital nonionic contrast medium utilized in the field of radiological imaging, particularly in X-ray procedures. The molecule's efficiency and utility are attributable to its three iodine atoms, which make up 45.6% of its molecular mass.

Chemical Composition and Properties

At the core of Iobitridol's efficacy is its inherent molecular structure, fortified by the presence of three iodine atoms. These iodine atoms contribute to a significant portion of its molecular weight, accounting for almost half at 45.6%. The nonionic nature of Iobitridol is contrasted by its water solubility, achieved through several hydroxyl (-OH) groups.

Commercial Formulations

One of the prominent commercial solutions containing Iobitridol is Xenetix 300, a product of Guerbet based in Roissy, France. This formulation offers Iobitridol at a concentration of 300 mg iodine/ml. The recommended dosage for optimal efficacy spans from 1.1 to 2.8 ml/kg of body mass, which translates to an iodine concentration of 0.33 to 0.84 g/kg within the human body.

Applications and Metabolism

Upon intravenous administration, Iobitridol undergoes renal filtration, ensuring its prompt and efficient elimination from the human system. Beyond X-ray imaging, its applications are diverse:

• Arthrography: Iobitridol aids in the visualization of joint spaces.
• Hysterosalpingography: The contrast agent is utilized to fill and delineate the uterus and fallopian tubes, assisting in the evaluation of potential pathologies or anatomical anomalies.

Its pharmacokinetic properties are optimized for safety, minimizing the risk of potential adverse reactions.

Conclusion

Iobitridol has carved out a significant niche in the realm of radiological imaging, offering enhanced visualization across a range of diagnostic procedures. With its unique balance of nonionic yet water-soluble properties, and its optimized commercial formulations, it stands as a testament to the advances in contrast media technology.

References

• Thomsen, H. S., & Morcos, S. K. (2003). Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. British Journal of Radiology, 76(908), 513-518.
• Spinazzi, A., Lorusso, V., Pirovano, G., & Taroni, P. (2002). Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Academic Radiology, 9, S305-S313.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!